Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $128.8052W HIGH $266.38
Volume
1.29 M
Value Traded
230.73 M
Short % Float
7.5%
-7.46%Week
-11.14%1 Month
-7.83%3 Month
+11.83%6 Month
+33.83%5 Year
+1,270.46%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
14.18 B
EPS (TTM)
14.49
P/E Ratio
15.07
Ent. Value
17.35 B
Total Shares
64.89 M
Float Shares
62.35 M
Insiders
3.95%
Institutions
99.93%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
JAZZ Catalyst Timeline
Dated clinical, regulatory and corporate events for Jazz Pharmaceuticals plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Jazz Pharmaceuticals plc
1209Total events
14Upcoming
346Tier-1 (high impact)
2012 to 2030Coverage
Upcoming catalysts 2
Event history 50
●Partnership / LicenseCorporate
Actio spun out new private entity holding non-ABS-1230 programs; Jazz received minority stake and related rights
▲Topline ReadoutZanidatamabApprovedClinical Data
Second interim top-line OS results from HERIZON-GEA-01
HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA)source ↗
●Debt Royalty FinancingCorporate
Pricing of $1.1 billion 1.875% exchangeable senior notes due 2032
●Equity OfferingCorporate
Concurrent ordinary share repurchases of approximately $225.0 million
◆Debt Royalty FinancingCorporate
Private offering of $1.0 billion exchangeable senior notes due 2032
▲FDA ApprovalZanidatamabApprovedFDA Decision
FDA approved Ziihera in combination with tislelizumab and chemotherapy for first-line HER2+ GEA
first-line treatment of adults with HER2+ (IHC 3+ and IHC 2+/ISH+) unresectable locally advanced or metastatic GEA, and Ziihera in combination with chemotherapy in the same setting for patients with HER2+ (IHC 3+) diseasesource ↗
●Oral PresentationZanidatamabApprovedPresentation
Investor webcast to discuss FDA approval and zanidatamab program updates
HER2+ advanced gastroesophageal adenocarcinomasource ↗
▲Priority ReviewZanidatamabApprovedRegulatory Filing
FDA granted Priority Review for zanidatamab sBLA in 1L GEA
first-line gastroesophageal adenocarcinoma (GEA)source ↗
▲Breakthrough Therapy DesignationZanidatamabApprovedDesignation
FDA granted Breakthrough Therapy designation for zanidatamab in HER2+ CRC
previously treated locally advanced, unresectable, or metastatic HER2-positive colorectal cancer (CRC)source ↗
▲Full ResultsZanidatamabApprovedClinical Data
Results from Phase 3 HERIZON-GEA-01 published in NEJM
first-line gastroesophageal adenocarcinoma (GEA)source ↗
●NDA SubmissionCannabidiolApprovedRegulatory Filing
NDA submitted for cannabidiol capsule formulation
currently approved indicationssource ↗
●Trial InitiationEpidiolexApprovedTrial
Phase 3b/4 trial in adult LGS initiated
adult Lennox-Gastaut syndrome (LGS)source ↗
▲Partnership / LicenseCorporate
Preclinical research collaboration with AbCellera announced
gastrointestinal (GI) cancers and other solid tumorssource ↗
◆Topline ReadoutZanidatamabApprovedClinical Data
Top-line results from second interim OS analysis for HERIZON-GEA-01 doublet regimen expected
first-line gastroesophageal adenocarcinoma (GEA)source ↗
●Timing GuidanceZepzelcaApprovedPresentation
Labeling supplement to remove second-line indication to be submitted
second-line metastatic SCLCsource ↗
▲Partnership / LicenseCorporate
Jazz and AbCellera announce preclinical research collaboration for T-cell engaging multispecific antibodies
gastrointestinal cancers and other solid tumorssource ↗
◆Oral PresentationXywavApprovedPresentation
Improvements in Sleep Inertia With Low-Sodium Oxybate Treatment in Participants With Narcolepsy Type 1 and Type 2 in the DUET Study
Narcolepsy Type 1 and Type 2source ↗
◆Late-BreakerXywavApprovedPresentation
Late-breaking presentations at SLEEP 2026 including DUET study data on individualized dosing
narcolepsysource ↗
◆Poster PresentationXywavApprovedPresentation
Clinically Relevant Symptoms of Narcolepsy and Idiopathic Hypersomnia in Patients Initiating Low-Sodium Oxybate: Electronic Health Record Notes Study
Narcolepsy and Idiopathic Hypersomniasource ↗
◆Oral PresentationXywavApprovedPresentation
Clinical Responders to Low-Sodium Oxybate in Narcolepsy and Idiopathic Hypersomnia
Narcolepsy and Idiopathic Hypersomniasource ↗
▼Topline ReadoutZepzelcaApprovedClinical Data
Top-line results from Phase 3 LAGOON trial: did not meet primary endpoint of overall survival
relapsed (second-line) metastatic small cell lung cancersource ↗
▼Primary Endpoint MissedZepzelcaApprovedClinical Data
Primary endpoint of overall survival not met in LAGOON trial
relapsed (second-line) metastatic small cell lung cancersource ↗
◆FDA Feedback ReceivedZepzelcaApprovedFDA Meeting
Shared LAGOON results with FDA; will discuss next steps regarding post-marketing requirements
relapsed (second-line) small cell lung cancersource ↗
◆Oral PresentationPresentation
Jazz management to participate in Jefferies Global Healthcare Conference fireside chat
▲Oral PresentationZanidatamabApprovedPresentation
Oral presentation at 2026 ASCO Annual Meeting of subgroup analyses
first-line gastroesophageal adenocarcinoma (GEA)source ↗
◆Oral PresentationLurbinectedinApprovedPresentation
Safety and PK in pediatric patients and preliminary antitumor activity in Ewing sarcoma (Rapid Oral Session)
relapsed/refractory solid tumors and Ewing sarcomasource ↗
◆Poster PresentationLurbinectedinApprovedPresentation
Real-world effectiveness and safety of lurbinectedin for previously treated ES-SCLC: Final primary and subgroup analysis
extensive-stage small cell lung cancersource ↗
◆Poster PresentationPresentation
Comparison of real-world OS between atezolizumab- and durvalumab-containing first-line regimens in ES-SCLC
extensive-stage small cell lung cancersource ↗
◆Poster PresentationZanidatamabApprovedPresentation
Combining zanidatamab, FOLFOX, and pembrolizumab as first-line therapy – Phase II ZANGEA trial
HER2/PD-L1-positive gastroesophageal adenocarcinomasource ↗
◆Oral PresentationZanidatamabApprovedPresentation
PD-L1 subgroup oral presentation at 2026 ASCO Annual Meeting
HER2-positive locally advanced or metastatic gastroesophageal adenocarcinomasource ↗
◆Oral PresentationPresentation
Jazz management to participate in TD Cowen Oncology Innovation Summit fireside chat
▲PublicationZanidatamabApprovedPresentation
Phase 3 HERIZON-GEA-01 results published in The New England Journal of Medicine
HER2-positive locally advanced or metastatic gastroesophageal adenocarcinomasource ↗
◆Oral PresentationPresentation
Jazz management to participate in RBC Global Healthcare Conference fireside chat
▲Priority ReviewZanidatamabApprovedRegulatory Filing
Zanidatamab sBLA for HER2+ 1L GEA granted Priority Review
HER2+ 1L GEAsource ↗
▲FDA Filing AcceptedZanidatamabApprovedRegulatory Filing
FDA accepted sBLA for Ziihera combinations in first-line HER2+ GEA with Priority Review
HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction, or gastroesophageal adenocarcinomasource ↗
▲Breakthrough Therapy DesignationZanidatamabApprovedDesignation
FDA granted Breakthrough Therapy designation for zanidatamab combination in first-line HER2+ GEA
HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinomasource ↗
◆Poster PresentationZanidatamabApprovedPresentation
Poster on AACR-ADOPT-GEA adaptive biomarker-driven trial at AACR 2026
gastroesophageal adenocarcinomasource ↗
◆Poster PresentationDordaviproneApprovedPresentation
Poster on dordaviprone and nuvisertib synergy in RCC at AACR 2026
renal cell carcinomasource ↗
◆Poster PresentationJZP898Presentation
Poster on JZP898 preclinical data at AACR 2026
solid tumorssource ↗
◆Oral PresentationPresentation
Oral presentation at 2026 AAN Annual Meeting
rare neurological disorderssource ↗
◆Poster PresentationPresentation
Poster presentations at 2026 AAN Annual Meeting
rare neurological disorderssource ↗
◆Oral PresentationZanidatamabApprovedPresentation
Oral presentation of NeoZanHER study at AACR 2026
early stage HER2 positive breast cancersource ↗
◆Oral PresentationPresentation
Jazz Pharmaceuticals to participate in fireside chat at Needham Healthcare Conference
Past FDA Catalysts and PDUFA Decisions
How JAZZ actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | Ziihera (zanidatamab-hrii) | Phase 3 topline data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B77 / 100
Pipeline Score
$12.9B
Pipeline Value
$18.5B
Commercial Value
Undervalued
Valuation Signal
30
Drugs Scored
3.0x
rNPV / MCap
Top 3%
Mid Cap(rank 21 of 660)
Percentile Rank
Jazz Pharmaceuticals plc holds a solid B-grade pipeline (77/100), with $15.1B risk-adjusted pipeline value, led by GWP42004 in Diabetes Mellitus, Type 2 (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $4.6B x 4.0 = $18.5B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Xywav | $1.8B | $1.5B | +14.6% |
| Epidiolex/Epidyolex | $1.1B | $996M | +13.6% |
| Rylaze/Enrylaze | $411M | $395M | +4.1% |
| Zepzelca | $377M | $302M | +24.8% |
| Defitelio/defibrotide | $220M | $212M | +3.6% |
| Modeyso | $137M | - | - |
| Xyrem | $135M | $180M | -24.9% |
| Vyxeos | $130M | $162M | -19.5% |
| Ziihera | $46M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GWP42004 Small moleculeCompletedNCT02053272 | Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 207 | Feb 1, 2016 |
Clinical Trial Results
Readouts, endpoints and source filings for every JAZZ program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Ziihera BreakthroughPriority | HER2+ gastroesophageal adenocarcinoma | Phase 3 | 2026-08-31 | statistically significant and clinically meaningful improvements in OS compared with trastuzumab plus chemotherapyRead More | Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced second interim top-line overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial...Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| GALA RENEE DDirector, Officer (President & CEO) | Sell | -2,000 141,394 held | $236.40 | 10/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in JAZZ
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 4.6 % (7 %) | 88.04 M | 365.34 K | -38.94% ( -232.99 K) |
JAZZ Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How JAZZ ranks across every disease it competes in
Competitive Position is a premium feature
See how JAZZ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialJAZZ News
JAZZJazz Pharmaceuticals Completes Acquisition of Actio Biosciences
Jazz Pharmaceuticals has successfully acquired Actio Biosciences for $820 million, enhancing its epilepsy pipeline with the addition of ABS-1230, a potential first-in-class therapy for KCNT1-related epilepsy. ABS-1230 has shown promising results in early trials, indicating significant seizure reductions in children. The acquisition aims to leverage Actio's precision biology expertise alongside Jazz's development capabilities.
Read more →JAZZJazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Jazz Pharmaceuticals has announced its participation in several upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference and the Citi 2026 Biopharma Back to School Summit. Management will engage in fireside chats to discuss the company's developments. Audio webcasts of these events will be available on their website.
Read more →JAZZZiihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA
Jazz Pharmaceuticals announced positive interim results from the Phase 3 HERIZON-GEA-01 trial, showing that Ziihera (zanidatamab-hrii) combined with chemotherapy significantly improves overall survival compared to trastuzumab plus chemotherapy for HER2+ gastroesophageal adenocarcinoma. The FDA recently approved Ziihera for first-line treatment, reinforcing its role as a new standard of care. The safety profile remains consistent with prior studies.
Read more →JAZZJazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
Jazz Pharmaceuticals has announced the pricing of an upsized $1.1 billion offering of 1.875% exchangeable senior notes due 2032. The offering, which includes an option for additional notes, is expected to close on August 31, 2026. Concurrently, the company plans to repurchase approximately $225 million of its ordinary shares. The proceeds from the notes will be used for general corporate purposes.
Read more →JAZZJazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
Jazz Pharmaceuticals has announced a private offering of $1.0 billion in exchangeable senior notes due 2032, aimed at qualified institutional buyers. The company will also repurchase up to $225 million of its ordinary shares concurrently with the offering. The proceeds from the offering are intended for general corporate purposes, although market conditions may affect the transaction.
Read more →JAZZU.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Jazz Pharmaceuticals announced FDA approval for Ziihera (zanidatamab-hrii) in combination with tislelizumab and chemotherapy for first-line treatment of advanced HER2-positive gastroesophageal adenocarcinoma. This approval establishes a new standard of care and is based on the HERIZON-GEA-01 trial results, which demonstrated significant improvements in overall and progression-free survival. The approval is significant for patients with limited treatment options.
Read more →JAZZJazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
Jazz Pharmaceuticals has announced its acquisition of Actio Biosciences for $820 million upfront, with potential additional payments of up to $500 million. This acquisition includes ABS-1230, a novel therapy for KCNT1+ epilepsy, a rare condition with no current FDA-approved treatments. The deal is expected to close in the fourth quarter of 2026, pending customary conditions.
Read more →JAZZJazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
Jazz Pharmaceuticals reported strong financial results for the second quarter of 2026, achieving record revenues of $1.2 billion, a 16% increase year-over-year. The company raised its revenue guidance for the year, anticipating continued growth driven by its key products, including Xywav and Epidiolex. Additionally, Jazz is preparing to launch its new drug Ziihera pending FDA approval.
Read more →JAZZJazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026
Jazz Pharmaceuticals has announced that it will report its second quarter financial results on August 3, 2026. The report will be released after the U.S. financial markets close, followed by a management-hosted webcast at 4:30 p.m. ET. Interested parties can register in advance for the call and access a replay via the company's website.
Read more →JAZZJazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and AbCellera (Nasdaq: ABCL) today announced a preclinical research collaboration, option and license...
Jazz Pharmaceuticals and AbCellera have announced a preclinical collaboration to develop T-cell engaging multispecific antibodies targeted at gastrointestinal cancers and other solid tumors. The agreement includes $56 million in upfront payments and up to $792 million in potential milestone payments. Jazz has the exclusive option to develop any therapeutic antibodies that result from the collaboration, further enhancing its oncology portfolio. This partnership is expected to leverage AbCellera's advanced antibody discovery capabilities to provide novel treatment options for difficult-to-treat cancers.
Read more →JAZZJazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the...
Jazz Pharmaceuticals showcased 11 late-breaking presentations at SLEEP 2026, highlighting the efficacy of Xywav in treating narcolepsy and idiopathic hypersomnia. The research emphasizes the importance of individualized dosing and potential cardiometabolic health benefits associated with Xywav's low-sodium formulation. Findings suggest meaningful health improvements for patients, establishing a comprehensive treatment paradigm that enhances patient quality of life. The data advances scientific understanding of complex sleep disorders, marking a significant milestone for Jazz Pharmaceuticals.
Read more →JAZZJazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
Jazz Pharmaceuticals announced that the Phase 3 LAGOON trial for Zepzelca (lurbinectedin) in second-line small cell lung cancer did not meet its primary endpoint of overall survival. Despite this, the safety profile remained consistent with previous data. The company plans to discuss the results with the FDA regarding post-marketing requirements for the second-line indication.
Read more →JAZZJazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP...
Jazz Pharmaceuticals announced that they will present 21 abstracts, including 11 late-breaking ones, at SLEEP 2026, showcasing ongoing research into the treatment of narcolepsy and idiopathic hypersomnia. The data emphasizes the effectiveness of their product, Xywav, which is the first FDA-approved treatment for idiopathic hypersomnia. This substantial presentation underscores the company's dedication to addressing challenging sleep disorders through clinical research and real-world evidence.
Read more →JAZZPhase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the New England Journal of Medicine has published the Phase 3 HERIZON-GEA-01 trial...
Jazz Pharmaceuticals announced the publication of Phase 3 HERIZON-GEA-01 trial results in the New England Journal of Medicine, which showcase the efficacy and safety of Ziihera (zanidatamab-hrii). The trial demonstrated significant improvements in progression-free survival and overall survival outcomes in patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. Additional analyses revealed consistent benefits across different PD-L1 expression levels, reinforcing zanidatamab's clinical potential. The findings could reshape first-line treatment expectations for this cancer indication.
Read more →JAZZ▲ +7.7%on this news
Jazz Pharmaceuticals Announces First Quarter 2026 Financial ResultsUSA - EnglishUSA - English
Jazz Pharmaceuticals reported a strong financial performance for Q1 2026, achieving total revenues of $1.1 billion, a 19% increase year-over-year. The company highlighted significant growth in its product lines, particularly Xywav and Epidiolex, and announced that zanidatamab's supplemental Biologics License Application was granted Priority Review. Despite a GAAP net loss due to litigation expenses, Jazz reaffirmed its revenue guidance for 2026.
Read more →JAZZJazz Pharmaceuticals Announces First Quarter 2026 Financial Results
Jazz Pharmaceuticals reported strong financial results for the first quarter of 2026, with total revenues reaching $1.1 billion, a 19% increase year-over-year. The company highlighted significant growth in its Xywav and Epidiolex products, alongside advancements in its pipeline, particularly with zanidatamab, which has been granted Priority Review by the FDA. The company remains optimistic about its financial guidance for the year, supported by strong commercial execution.
Read more →JAZZJazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Jazz Pharmaceuticals announced the FDA's acceptance of the supplemental Biologics License Application for zanidatamab in combination therapies for HER2-positive gastroesophageal adenocarcinoma. The application is supported by data from the HERIZON-GEA-01 trial, which demonstrated significant clinical benefits. The FDA has set a target action date of August 25, 2026, for the review.
Read more →JAZZJazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026
Jazz Pharmaceuticals has announced it will release its first quarter financial results for 2026 on May 5, 2026. The results will be shared after the U.S. markets close, followed by a webcast hosted by company management. This event will provide insights into the company's business and financial status.
Read more →JAZZJazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin) Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present three rapid oral and seven poster...
Jazz Pharmaceuticals plc announced its participation in the upcoming ASCO 2026 Annual Meeting, where it will present multiple studies related to zanidatamab and lurbinectedin. The key presentations will focus on zanidatamab's performance in advanced HER2-positive gastroesophageal adenocarcinoma and real-world data on the safety and effectiveness of lurbinectedin in extensive-stage small cell lung cancer. This initiative highlights Jazz's commitment to advancing treatment options through innovative research and collaboration.
Read more →About Jazz Pharmaceuticals plc
HeadquartersFIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN, D04 E5W7
BIOPHARMAWATCH ELITE PLUS
Trade the next JAZZ catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime